Literature DB >> 22549759

Appropriate timing of coronary artery bypass grafting after acute myocardial infarction.

Alexander Assmann1, Udo Boeken, Payam Akhyari, Artur Lichtenberg.   

Abstract

OBJECTIVES: Optimal timing of coronary artery bypass grafting (CABG) after acute myocardial infarction (AMI) remains the subject of fierce debate. Therefore, the recommended deferral ranges from immediate intervention to surgery 4 weeks after infarction. Especially, the increasing cohorts of patients at old age or with poor left ventricular function, whose mortality rates are additionally enhanced, may profit from focused analyses. This study aims at clarifying the appropriate timing of CABG after AMI, with special regard to high-risk patients (Age >70 years, left ventricular ejection fraction (LVEF) <30%).
METHODS: Retrospective analysis was performed in 3475 patients who had undergone isolated CABG between 2005 and 2009. Those 1168 patients with previous AMI (<30 days) were categorized in groups, depending on deferral of surgery: <6 hours after AMI (A), 6 hours-1 day (B), 2-3 days (C), 4-10 days (D), 11-20 days (E), and 21-30 days (F). Furthermore, subgroups with an age >70 years or a LVEF <30% were examined.
RESULTS: The mortality rates in groups A-F were 14.8, 10.2, 8.8, 4.2, 2.3, and 2.0%, whereas only the values of groups A-D were significantly increased versus the mortality rate of patients without previous AMI (1.9%). In patients over 70 years, we observed operative mortalities of 26.3, 14.3, 11.9, 6.1, 4.2, and 3.1% (groups A-F) versus 2.5% (no previous AMI), while 27.4, 15.4, 11.7, 6.0, 3.7, and 2.8% (groups A-F) versus 2.7% (no previous AMI) of patients with a LVEF <30% died during the first 30 days after surgery. In both subanalyses of high-risk patients, the enhanced mortalities of groups A-E reached significance. Multivariate analysis of operative risk factors revealed that CABG within 10 days after AMI and age over 60 years are independently associated with operative mortality.
CONCLUSIONS: CABG early after AMI (<10 days) is accompanied by significantly increased mortality, especially in elderly patients or in patients with a severely impaired LVEF. At least the critical time period of 3 days should be avoided-whenever the hemodynamics is stable enough. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22549759     DOI: 10.1055/s-0032-1304542

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  5 in total

1.  Preoperative risk factors in 10 418 patients with prior myocardial infarction and 5241 patients with prior unstable angina undergoing elective coronary artery bypass graft surgery.

Authors:  A Bottle; A Mozid; H P Grocott; M R Walters; K R Lees; P Aylin; R D Sanders
Journal:  Br J Anaesth       Date:  2013-04-16       Impact factor: 9.166

2.  Optimal Timing of Surgical Revascularization for Myocardial Infarction and Left Ventricular Dysfunction.

Authors:  Rong Wang; Nan Cheng; Cang-Song Xiao; Yang Wu; Xiao-Yong Sai; Zhi-Yun Gong; Yao Wang; Chang-Qing Gao
Journal:  Chin Med J (Engl)       Date:  2017-02-20       Impact factor: 2.628

3.  Timing of coronary artery bypass grafting after acute myocardial infarction: does it influence outcomes?

Authors:  Anton Prem Thilak; Devika Thacker; Sufina Shales; Debasis Das; Sukanta Kumar Behera; Arup Kumar Ghosh; Pradeep Narayan
Journal:  Kardiochir Torakochirurgia Pol       Date:  2021-05-15

4.  Appropriate Timing of Coronary Artery Bypass Graft Surgery for Acute Myocardial Infarction Patients: A Meta-Analysis.

Authors:  Qianlei Lang; Chaoyi Qin; Wei Meng
Journal:  Front Cardiovasc Med       Date:  2022-03-28

5.  Immediate surgical coronary revascularisation in patients presenting with acute myocardial infarction.

Authors:  Nawid Khaladj; Dmitry Bobylev; Sven Peterss; Sabina Guenther; Maximilian Pichlmaier; Erik Bagaev; Andreas Martens; Malakh Shrestha; Axel Haverich; Christian Hagl
Journal:  J Cardiothorac Surg       Date:  2013-07-03       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.